Page 119 - Read Online

Chia et al. Hepatoma Res 2019;5:9 I http://dx.doi.org/10.20517/2394-5079.2018.112 Page 11 of 14

inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J
Neuroinflammation 2011;8:49.
40. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in
hepatocellular carcinoma. Oncogene 2011;30:1229-40.
41. Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer 2017;116:415-23.
42. Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, et al. The expression of Axl receptor tyrosine kinase influences the tumour
phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br J Cancer 2013;108:621-8.
43. Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early
stage hepatocellular carcinoma. Int J Cancer 2015;137:385-94.
44. Nordberg J, Arnér ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med
2001;31:1287-312.
45. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, et al. Thioredoxin expression is associated with lymph node
status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.
46. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, et al. Increased expression of thioredoxin-1 in human colorectal cancer
is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.
47. Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget
2015;6:9551-63.
48. Yang J, Li J, Dai W, Wang F, Shen M, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis.
Exp Ther Med 2015;9:1413-20.
49. Jin D, Tao J, Li D, Wang Y, Li L, et al. Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion.
Oncotarget 2015;6:33523-33.
50. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi Protein GP73 produces
marker for hepatocellular carcinoma. Traffic 2007;8:1415-24.
51. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral
liver disease. Hepatology 2002;35:1431-40.
52. Mao Y, Yang H, Xu H, Lu X, Sang X, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut
2010;59:1687-93.
53. El-Abd N, Fawzy A, Elbaz T, Hamdy S. Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma. Tumor
Biol 2016;37:211-6.
54. Attallah AM, El-Far M, Malak CA, Omran MM, Shiha GE, et al. HCC-DETECT: a combination of nuclear, cytoplasmic, and
oncofetal proteins as biomarkers for hepatocellular carcinoma. Tumor Biol 2015;36:7667-74.
55. Attallah AM, El-Far M, Abdel Malak CA, Farid K, Omran MM, et al. A simple diagnostic index comprising epithelial membrane
antigen and fibronectin for hepatocellular carcinoma. Ann Hepatol 2015;14:869-80.
56. Mao L, Wang Y, Wang D, Han G, Fu S, et al. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing
AFP-negative hepatocellular carcinoma. PLoS One 2017;12: e0183880.
57. Filmus J. The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J
2002;19:319-23.
58. Veugelers M, De Cat B, Ceulemans H, Bruystens AM, Coomans C, et al. Glypican-6, a new member of the glypican family of cell
surface proteoglycans. J Biol Chem 1999;274:26968-77.
59. Traister A, Shi W, Filmus J. Mammalian Notum induces the release of glypicans and other GPI anchored proteins from the cell
surface. Biochem J 2008;410:503-11.
60. Nakatsura T1, Kageshita T, Ito S, Wakamatsu K, Monji M, et al. Identification of glypican-3 as a novel tumor marker for melanoma.
Clin Cancer Res 2004;10: 6612-21.
61. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma:
biological significance and temporospatial distribution. Cancer Res 1997;57:5179-84.
62. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, et al. Enhanced glypican-3 expression differentiates the majority of
hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-64.
63. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, et al. Glypican-3, overexpressed specifically in human hepatocellular
carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
64. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, et al. Identification of soluble NH2-terminal fragment of glypican-3
as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
65. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt
signaling. Cancer Res 2005;65:6245-54.
66. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008;9:224.
67. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008;7:2787-90.
68. Feitelson MA, Sun B, Tufan NLS, Liu J, Pan J, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-604.
69. Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res 2002;67:112.
70. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-12.
71. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-10.
72. Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor.
Am J Resp Cell Mol Biol 2003;29:694-701.
73. Capurro MI, Xu P, Shi W, Li F, Jia A, et al. Glypican-3 inhibits hedgehog signaling during development by competing with Patched
for Hedgehog binding. Dev Cell 2008;14:700-11.